Amaya Gascó MD PhD

#ASCO25 1st practice changing presentation, which has already been our practice since the initial readout for our patients with #BRAFV600E mutant colorectal cancer. More options for our patients.👏🏽 @OncoAlert

Amazing #ISLB24 congress in summary: 303 participants, 24 countries 🌎 100 abstracts 📝 50 speakers 👨‍🏫👩‍🏫 26 travel awards ✈️ 3 ISLB awards🥇 32 sponsors 5 satellite symposium ✏️ THAKS ALL OF YOU “THE” INTERNATIONAL LIQUID BIOPSY SOCIETY IS GROWING EVERY YEAR ! @isliquidbiopsy

Continuing with a satellite symposium at #ISLB24 by @FoundaATCG discussing on they new pipeline and concepts as Tumor Fraction data. @ValsamoA @isliquidbiopsy

More insights from the plenary session “AI at the Interface: Accelerating Evidence Generation, Advancing Disparities Research, and Improving Trial Design” at the #AACR24 Annual Meeting at the link here: aacrmeetingnews.org/news/plenary-s…

@MacarullaTeresa @vallhebron @Ja_Capdevila @elena_elez @TaberneroJosep Enhorabuena!!! Súper merecido!

Un honor poder liderar la Unitat de Tumors Gastrointestinals i Endocrins del Servei d’ Oncologia de @vallhebron, @Ja_Capdevila @elena_elez @TaberneroJosep

Día Mundial Cáncer Campaña Ejercicio youtu.be/CwtjhkfO6jQ?si… a través de @YouTube

On #WorldHeadandNeckCancerDay, we raise awareness for head and neck cancer and the unmet need for patients. Access resources from the @Ifhnos_official and learn how to support those living with head and neck cancer: ifhnos.net/whncd/Index/

Kura Oncology is proud to announce a new trial opening later this year, FIT-001, a clinical trial assessing the safety, tolerability, and preliminary clinical activity in KO-2806, a next generation FTI, in adults with solid tumors. Learn more: #farnesyl-transferase-inhibitor" target="_blank" rel="nofollow noopener">kuraoncology.com/clinical-trial…

Gracias y enhorabuena a lFundación Ricky Rubio y Dr Santiago Viteri por esta segunda edición del CECOB

Today at the @EHA_Hematology Annual Congress, we’re presenting the latest data on our potential best-in-class menin inhibitor #ziftomenib for NPM1-mutant #AML. Highlights include 35% complete remission rate and favorable safety profile and tolerability. Read more: bit.ly/3P7dJFs #EHA2023

#UAlbany very excited to celebrate and support #OpenGovWeek! Some great pics of CTG @ualbany and @RockefellerColl's @MilaGasco with other #OpenGov experts in Lima, Perú. Thank you @SGP_PCM for hosting and taking good care of Mila! @opengovpart @GIGAPP @RIGA_LATAM @RAGA_Int @Agov

#OpenGovWeek #GobiernoAbiertoPerú Conferencia de @MilaGasco de @CTGUAlbany empezamos el día 2. @SGP_PCM @RAGA_Peru @jcpascoh @redmatriz fb.watch/krnpm4IY2S/?mi…

Enhorabuena a @SGP_PCM y a @jcpascoh por organizar una mesa redonda con tan buenos profesionales y amigos. Tuvo que ser excepcional escuchar juntos a @EsterKaufman @MilaGasco y @redmatriz Ojalá haya vídeo! #OpenGovWeek

Describe approaches to address variances in care for patients with thoracic malignancies at this year's ILC.

📢Hoy en la Semana del Gobierno Abierto 2023: conferencias de @MilaGasco y @redmatriz sobre iniciativas, retos y experiencias latinoamericanas. 🕗Inscritos: ingreso desde 8:00am 💻Transmisión en vivo: facebook.com/sgp.pcm #OpenGovWeek #GobiernoAbierto #GestiónPública

Proud of being part of this amazing scientific-driven and patient-oriented company. Thank you Kura Oncology for this great opportunity!!!

HPV-16/18 DNA vaccine MEDI0457 is safe and efficacious in patients with recurrent/metastatic head and neck squamous cell carcinoma. Efficacy endpoint was not reached but Aggarwal et al showed early and durable clinical responses. bit.ly/3GMGD96 @CharuAggarwalMD @agasco

People who received an Omicron booster were more than 18 times less likely to die from Covid and 3 times less likely to be infected compared to unvaccinated people, according to the latest CDC data.

Happy and proud to have been part of this exciting Trastuxumab Deruxtecan journey and to have provided the HER2m lung cancer patients another amazing treatment option!!!! ascopost.com/news/august-20…